Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Beijing Konruns Pharmaceutical Co., Ltd. specializes in the development and manufacturing of high-quality biopharmaceutical products, particularly in the areas of oncology and autoimmune diseases. The company has established a strong competitive position in the Chinese market, driven by its innovative drug pipeline and robust partnerships with healthcare institutions.
Konruns generates revenue primarily through the sale of its proprietary biopharmaceutical products, which command premium pricing due to their efficacy and safety profiles. The company benefits from strong intellectual property protections and a growing demand for innovative treatments in China.
Approval of new drug applications by the National Medical Products Administration (NMPA)
Partnership announcements with major healthcare providers
Clinical trial results for pipeline products
Changes in regulatory policies affecting biotechnology
Regulatory changes that could impact drug approval processes
Technological disruption in biopharmaceutical manufacturing
Emergence of generic competitors for existing products
Increased competition from other biotech firms in China
Potential liquidity issues if R&D projects do not yield timely results
Low ROE of 5.3% may indicate limited returns on equity investments
moderate - As a biotechnology firm, Konruns is somewhat insulated from economic downturns due to the essential nature of healthcare, but overall spending on pharmaceuticals can be affected by GDP growth.
Higher interest rates could increase the cost of financing for R&D projects, potentially impacting future growth. Additionally, higher rates may lead to reduced consumer spending on healthcare services.
minimal - The company's low debt-to-equity ratio of 0.10 indicates a strong balance sheet with minimal reliance on credit.
growth - Investors seeking exposure to innovative biopharmaceuticals with high growth potential.
high - The stock has shown significant volatility, with a 1-year return of -43.4%, indicating a high-risk profile.
